|
Title
|
|
|
|
Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| The medical claims data of approximately 20 million patients was analyzed from the beginning of 2001 through December 2004. Patients with breast, prostate, or lung cancer or multiple myeloma were eligible for inclusion. Claims associated with surgery to the maxilla or mandible were included if they were registered after treatment with a bisphosphonate (BP) was initiated (Figure 1). The median age of intravenous (IV) users (64 years) was higher than patients on oral BPs (59 years), but compared with never-users no statistically significant difference was found. Data on gender distribution, disease severity, or indication for BP use was not provided by the authors. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The journal of evidence-based dental practice. - St. Louis, MO, 2001, currens
Journal of evidence-based dental practice. - Saint Louis, Ill.
|
|
|
Publication
|
|
|
|
St. Louis, MO
:
Mosby, Inc
,
2007
|
|
|
ISSN
|
|
|
|
1532-3382
|
|
|
DOI
|
|
|
|
10.1016/J.JEBDP.2007.05.013
|
|
|
Volume/pages
|
|
|
|
7
:3
(2007)
, p. 132-135
|
|
|
Number
|
|
|
|
1532-3382
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|